In this article, we will look at the 10 Best Strong Buy Stocks to Buy Under $10.
On July 29, Michael Arone, State Street chief investment strategist, appeared on CNBC’s ‘Power Lunch’ to talk about the ongoing market rally and why nothing is stopping it.
He stated that there are a couple of factors behind this, including an improvement in trade, as more trade deals continue to be announced. He expects free cash flow windfall from the one big beautiful bill to also be a tailwind for many companies, especially those that spend considerable amounts of money on R&D.
Dollar weakness is another factor he cited, as more than 40% of the S&P 500 revenues come from outside the US, making it a tailwind, especially for tech companies.
READ ALSO: 10 Most Undervalued Blue Chip Stocks to Buy According to Hedge Funds and 11 Most Oversold Energy Stocks To Buy Right Now.
Despite lofty valuations, Arone expects the market rally to continue. An increase in trade deals, earnings growth, and AI spending is anticipated to push stocks even higher. The strategist also stated that he favors technology, communication services, industrials, and financials.
With these trends in view, let’s look at the best strong buy stocks to invest in under $10.
A business executive examining a financial index chart, illustrating the company’s involvement in the global stock market.
Our Methodology
We used Finviz and Tipranks to make a list of strong buy stocks with a stock price under $10 and selected the top 10 with consensus Strong Buy ratings and the highest number of hedge fund holders as of Q1 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database, and also added the analyst upside potential for each stock. The list is sorted in ascending order of hedge fund holders.
Note: All data was sourced on July 29.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Best Strong Buy Stocks to Buy Under $10
10. Denison Mines Corp. (NYSE:DNN)
Stock Price: $2.10
Analyst Upside: 30.53%
Number of Hedge Fund Holders: 23
Denison Mines Corp. (NYSE:DNN) is one of the best strong buy stocks to buy under $10. On July 18, Raymond James raised the firm’s price target on Denison Mines Corp. (NYSE:DNN) to C$3.80 from C$3.70, keeping an Outperform rating on the shares.
The rating update came after Denison Mines Corp. (NYSE:DNN) announced on July 16 the discovery of additional high-grade mineralization “around 40 meters outside of the previously estimated mineralized domain associated with the D1 lens of the Gryphon uranium deposit”.
Management reported that the discovery was a part of the successful delineation drill program carried out at Gryphon during the first half of 2025. Results from the delineation drilling program are anticipated to bolster confidence for the previously projected mineral resources for Gryphon.
Denison Mines Corp. (NYSE:DNN) is involved in the exploration and development of uranium. The company holds interests in the Athabasca Basin, Wheeler River, Midwest Project, McClean Lake, and Waterbury Lake.
9. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Stock Price: $8.11
Analyst Upside: 48.06%
Number of Hedge Fund Holders: 30
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best strong buy stocks to buy under $10. In a report released on July 25, Les Sulewski from Truist Financial maintained a Buy rating on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a price target of $8.00.
The rating update followed Amneal Pharmaceuticals, Inc.’s (NASDAQ:AMRX) announcement of certain unaudited preliminary financial results for fiscal Q2 on July 21. The company has plans to report the actual Q2 2025 results on August 5.
The unaudited preliminary financial results for the quarter showed a net revenue of $720 million to $730 million, suggesting an increase of around 3% versus the same period last year. Adjusted EBITDA rose around 13% to $180 million to $185 million, with income before income taxes of $45 million to $56 million, compared to $20 million in the same period in 2024.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a medicine company that provides pharmaceuticals. The company’s product portfolio encompasses biosciences, specialty, generics, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.
